Patient-Derived Xenografts to Reduce Cancer Health Disparities
This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.
Checked against the public recordLast updated Aug 20, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University of California, Davis
- Interventions being studied
- Procedure: Biospecimen Collection
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patient receiving treatment for the above 4 cancers (bladder cancer, lung cancer, gastric/stomach cancer, and liver cancer) * Signed informed consent that will be put on file Exclusion Criteria: * No informed consent obtained * Specimen unacceptable/degraded/etc. * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners * Adults unable to consent
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- UC Irvine Health/Chao Family Comprehensive Cancer CenterOrange, California
- University of California Davis Comprehensive Cancer CenterSacramento, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 20, 2026. Always confirm current availability with the study team.